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FIGURE 1 How the Dose-Length Product to
E/DLP Varies With Anatomical Position Along an
Anthropomorphic Phantom
The typical anatomical coverage of a chest and a cardiovascular
computed tomography scan is indicated by the blue and red
lines, respectively. E/DLP ¼ effective dose conversion factor;
ICRP ¼ International Commission on Radiological Protection.
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957applied to individual patients, the variety of quoted
ﬁgures requires resolution. Those that are routinely
cited in published reports include the thoracic con-
version factors of 0.017 or 0.014 mSv/mGycm (3),
which estimate the effective dose as deﬁned in
International Commission on Radiological Protection
publication 60, and speciﬁc cardiovascular CT
conversion factors of approximately 0.028 (4),
which estimate the effective dose as deﬁned in
International Commission on Radiological Protection
publication 103. Pediatric conversion factors are even
more contentious. Because cardiovascular CT does
not usually involve scanning the whole of the thorax,
and it also predominantly involves exposure over
highly radiosensitive breast tissue, an effective dose
for any given dose-length product is proportionally
higher for cardiac versus thoracic CT (Figure 1).
The issue of dose reference levels for cardiovas-
cular CT is also important, and a recent survey of
cardiovascular CT centers in the United Kingdom
performed by the British Society of Cardiovascular CT
revealed a 5-fold variability in median dose-length
product for standard CT coronary angiography from
200 mGycm to more than 1,000 mGycm. Assuming all
images were diagnostic and scans were performed on
appropriate cardiac enabled scanners, this is alarm-
ing. However, given the evidence that the majority of
UK centers perform low volumes of scans, with only a
handful performing more than 1,000 scans each year
(5), this may not be surprising. The challenge,
however, is how to determine a suitable dose
reference level with such variation in both number
and dose.Only when we, as a clinical and scientiﬁc commu-
nity, have rationalized and agreed on these values
will discussions with our patients regarding dose be
evidence based and meaningful.Isabel Castellano, PhD
*Edward D. Nicol, MD, MBA
*Department of Cardiovascular CT
Royal Brompton & Hareﬁeld NHS Foundation Trust
London, England
E-mail: e.nicol@rbht.nhs.uk
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Int J Cardiol 2013;168:3001–3.REPLY: The Murky World of Effective Dose
for Cardiovascular CTWe thank Drs. Castellano and Nicol for their interest
in our paper (1) and their many insightful comments,
which focus speciﬁcally on the radiation dose for
patients undergoing cardiovascular computed
tomography (CT). The central themes of their letter
are the challenges involved in estimating the
effective dose from the dose-length product (DLP),
the present lack of and need for diagnostic reference
levels (DRLs) for cardiovascular CT, and the great
variability in radiation doses from coronary CT
angiography (CTA). We share all of these concerns.
The thoracic conversion factors of 0.017 and
0.014 mSv $mGy1 $ cm1, which are routinely used in
published reports, are indeed inadequate for
estimating an effective dose from CTA, resulting in
substantial underestimation. As we have previously
pointed out (2), these values were derived fromMonte
Carlo simulations of ancient single-slice scanners
incapable of performing CTA and using an older
deﬁnition of effective dose. Figure 1 in the letter by
Drs. Castellano and Nicol is a wonderful illustration
of why the effective dose from coronary CTA should
be higher than that from a chest CT with the same
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958DLP. In any event, just because radiation dose is
difﬁcult to estimate does not mean that it should not
be openly discussed with patients, especially because
it is a public concern. We are currently working on a
more accurate approach for estimation of effective
dose from DLP for coronary CTA for virtually all
contemporary scanners.
One of the goals of our paper was to stimulate
awareness of the need for DRLs in all cardiovascular
procedures involving ionizing radiation, of which
coronary CTA is an important example. This is an
area in which the cardiology community has fallen
behind other ﬁelds (e.g., pediatric radiology). DRLs
for individual examinations are often framed in
terms of the 75th percentile of the distribution of
patient doses in a particular population. However,
with such high between-center variability, as pointed
out by Drs. Castellano and Nicol, careful thought is
needed for the most constructive approach to devel-
oping such reference levels. If a population-based
75th percentile threshold were used uniformly, most
patients would be ﬂagged as exceeding the DRL
in some laboratories; consequently, the concept
of DRL could be rendered of little use for patient
radiation protection.
Another important implication of the great vari-
ability in radiation doses is that, in real-world prac-
tice, doses may not be nearly as low as those reported
by experts using the latest equipment in selected
patient populations. Thus, to paraphrase Mark Twain,
rumors of the demise of the “radiation problem” in
cardiac imaging have been greatly exaggerated. The
UK laboratories’ median coronary CTA DLP range of
200 to 1000 mGycm suggests that, using a cardiac-
speciﬁc conversion factor, the median coronary CTA
effective dose at these sites ranged fromw5 to 30 mSv.
The existence of such dose levels in contemporary
practice underscores both the need for continued
efforts to reduce doses to patients and the need for
patient-centered imaging, shared decision making,
and better communication with our patients.*Andrew J. Einstein, MD, PhD
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Thomas C. Gerber, MD, PhD
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for Cardiovascular CTThe letter by Drs. Castellano and Nicol in response to
my editorial introduces an additional complexity
regarding radiation exposure from cardiovascular
computed tomography (CT), namely the difﬁculty in
measuring the actual dose that any given patient re-
ceives. Because of this difﬁculty and lack of agree-
ment on what to measure and how to express the
result, a measurement is not even attempted on a
regular basis in clinical practice. Most imaging sites
use a generic estimate of radiation exposure that is
included in the report of ﬁndings.
In either case, that is, trying to obtain an accurate
measurement in each patient with all the unknowns
and difﬁculties mentioned by Castellano and Nicol
or using a generic estimate of radiation exposure,
the ordering physician and the imaging center need
the guidelines provided in the report by Einstein
et al. so that a meaningful discussion of the issues
of radiation exposure can be initiated with the
patient.
I agree with the conclusion of Drs. Castellano
and Nicol that, until the scientiﬁc community can
agree on how to obtain these measurements and
how best to express them to patients, discussions
with our patients will lack some degree of unifor-
mity. It would be a stretch to say that these discus-
sions are evidence based. For the vast majority of
patients, this is irrelevant; however, the real issue is
understanding the “risk,” not the details of actual
exposure to radiation.*Lewis Wexler, MD
*Department of Radiology
Stanford University School of Medicine
805 Tolman Drive
Stanford, California 94305-1025
E-mail: lew.wexler@stanford.edu
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